Werewolf Therapeutics, Inc.
NasdaqGS:HOWL
Sector
Industries
Location
Market Cap
USD 53.85 M
Share Price
USD 1.20
Avg Daily Volume
542,879
Change (1 day)
-7.69%
Change (1 year)
-51.02%
Change (YTD)
-18.92%
Werewolf Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2024: -3,583.77%
Werewolf Therapeutics, Inc. EBIT Margin is -3,583.77% for the Trailing 12 Months (TTM) ending December 31, 2024, a 1,835.68% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
-
Werewolf Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2023 was -185.14%, a -47.16% change year over year.
-
Werewolf Therapeutics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2022 was -350.36%.
StockViz
Competitors
Biomea Fusion, Inc.
USD 1.66
BMEA
+0.01
0.61%
Edgewise Therapeutics, Inc.
USD 14.23
EWTX
+0.28
2.01%
Design Therapeutics, Inc.
USD 4.03
DSGN
+0.05
1.26%
Ikena Oncology, Inc.
USD 17.16
IKNA
+0.72
4.38%
Key Data
| Date | EBIT Margin | EBITDA Margin | Net Income Margin | EBT Margin |
|---|